Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 06 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 Oct 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.